医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate Tests

2021年06月08日 PM09:00
このエントリーをはてなブックマークに追加


 

SOUTH SAN FRANCISCO, Calif.

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 Kappa (B.1.617.1) variant strain. The company is also working on controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants. All three variants were first identified in India.

“The number of people receiving vaccinations in the United States and many other countries continues to grow rapidly,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Unfortunately, India is experiencing a massive outbreak and overwhelming challenge with new viral variants and a largely unvaccinated population. We remain steadfast in our commitment to provide tools to eradicate this virus worldwide, including positive RNA controls that can be used in tests that monitor and detect new variants of SARS-CoV-2 as well as a full line of products to fight infectious disease.”

For more information on the Twist products to combat COVID-19, including a full suite of NGS testing panels to help track the emergence of new SARS-CoV-2 strains, please visit: https://www.twistbioscience.com/coronavirus-research-tools.

In March 2020, Twist launched its first synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2. These controls continue to be included in many different assays worldwide and can be used to determine the limit of detection, monitor day-to-day test variations and are included on the U.S. Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2. Twist has subsequently released additional SARS-CoV-2 controls to cover the evolution of the virus and remains committed to using its DNA synthesis platform to offer valuable products that improve health and sustainability.

The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified. For customers interested in alternative variants of SARS-CoV-2, or synthetic RNA or DNA controls for other sequences, Twist can provide custom controls in multiple formats. Twist also offers a suite of research tools, including next-generation sequencing (NGS) products for SARS-CoV-2 as well as a broad respiratory panel and the most comprehensive viral panel.

Customers purchasing synthetic controls are subject to Twist’s leading biosecurity screening protocols and applicable laws and regulations.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to deliver synthetic controls for SARS-CoV-2 to its customers, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005462/en/

CONTACT

Angela Bitting

SVP, Corporate Affairs

925- 202-6211

abitting@twistbioscience.com

同じカテゴリーの記事 

  • アクティビストキャンペーンサイトStrengthen Wakamoto(TOKYO:4512)の公開:株式会社ナナホシマネジメント
  • Nanahoshi Management Ltd.: Strengthen Wakamoto Activist Campaign (TOKYO:4512) Is Released
  • 冠科生物连续三年荣膺T+ Employer® 卓越雇主
  • Crown Bioscienceが3年連続でT+ Employer®に認定される
  • Better Foods of Shinsegae Food Participates in NPEW to Accelerate Entry to U.S. Plant-based Food Market